Fusion protein technologies for biopharmaceuticals : applications and challenges /

• Άλλοι συγγραφείς: Schmidt, Stefan R.
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Hoboken, New Jersey : John Wiley & Sons, [2013]
• Θέματα: Biopharmaceutics.; Pharmaceutical biotechnology.; Drug carriers.; Immunotoxins > Therapeutic use.; Protein engineering.; Recombinant fusion proteins > Therapeutic use.; MEDICAL > Pharmacology.; Recombinant Fusion Proteins > therapeutic use.; Drug Carriers.; Immunotoxins > pharmacokinetics.; Immunotoxins > therapeutic use.; Protein Engineering.; Recombinant Fusion Proteins > pharmacokinetics.; Electronic books.
• Φυσική περιγραφή: 1 online resource.
• Βιβλιογραφία: Includes bibliographical references and index.
• ISBN: 9781118354582; 1118354583; 9781118354575; 1118354575; 9781118354568; 1118354567; 9781118354599; 1118354591; 9781299241954; 1299241956
• DOI: 10.1002/9781118354599

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei.